Back to today’s briefing

Story perspectives

New Oral Diabetes Drug Shows Promise in Trials

4/29/2025

32 6

Summary

Story summary

ORforglipron, a groundbreaking oral medication from Chugai Pharmaceutical and Eli Lilly, is currently undergoing phase 3 trials for type 2 diabetes and obesity. Early results are promising, showcasing notable drops in A1C levels and weight loss. If successful, this innovative non-peptide treatment could transform the landscape of diabetes and obesity management.

1 of 1

Story summary

ORforglipron, a groundbreaking oral medication from Chugai Pharmaceutical and Eli Lilly, is currently undergoing phase 3 trials for type 2 diabetes and obesity. Early results are promising, showcasing notable drops in A1C levels and weight loss. If successful, this innovative non-peptide treatment could transform the landscape of diabetes and obesity management.